国产精品av在线观看不_日韩久久美女毛片_黄色网站在线性爱视频_9691精品人妻无码久久久_成年AV免费网址大全超清_亚洲aⅴ天堂无码_曰本裸色私人影院噜噜噜影院_另类视频无码视频国产精品_网红三级在线播放_美腿丝袜在线观看

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the results of an interim analysis of a Phase Ib/II clinical study (Study 218) of its in-house discovered and developed anticancer agent eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: Halaven?, “eribulin”) in combination with the anti-PD-1 antibody pembrolizumab developed by Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the U.S. and Canada), in patients with metastatic triple-negative breast cancer have been presented at the 39th Annual San Antonio Breast Cancer Symposium held from December 6 to 10, 2016. Development of this combination regimen is being conducted jointly under the cooperation of both companies.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts highlighting the latest clinical data on its in-house developed halichondrin class microtubule dynamics inhibitor eribulin mesylate (product name: Halaven?, “eribulin”) will be presented at the San Antonio Breast Cancer Symposium (SABCS2016) taking place in San Antonio, the United States, from December 6 to 10.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that Eisai has been highly commended for its initiatives to promote access to medicines and ranked 11th among the world’s leading pharmaceutical companies in the Access to Medicine Index (ATM Index) 2016.

Harvard Business Review has just announced The Best-Performing CEOs in the World, in which CEO Haruo Naito was ranked 87th. Among Japanese companies, only three other CEOs made the list, including Nidec’s Shigenobu Nagamori (42nd), FAST RETAILING’s Tadashi Yanai (46th) and Softbank’s Masayoshi Son (73rd).

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its U.S. subsidiary Eisai Inc. has launched BELVIQ XR? 20mg tablets, a new once-daily formulation of BELVIQ? (generic name: lorcaserin hydrochloride) for chronic weight management in the United States.